No Data
No Data
Netflix To Rally More Than 55%? Here Are 10 Top Analyst Forecasts For Monday
Sarepta Therapeutics Is Maintained at Overweight by Piper Sandler
Analysts' Top Healthcare Picks: Sarepta Therapeutics (SRPT), Evolent Health (EVH)
Analysts Conflicted on These Healthcare Names: Apellis Pharmaceuticals (APLS), Skye Bioscience (SKYE) and Sarepta Therapeutics (SRPT)
BofA Securities Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $157
Express News | Sarepta Therapeutics Inc : Piper Sandler Cuts Target Price to $110 From $182